Molecular profiling in the treatment of colorectal cancer: Focus on regorafenib

Yiyi Yan, Axel F Grothey

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.

Original languageEnglish (US)
Pages (from-to)2949-2957
Number of pages9
JournalOncoTargets and Therapy
Volume8
DOIs
StatePublished - Oct 15 2015

Fingerprint

Colorectal Neoplasms
Therapeutics
Biological Therapy
Genetic Markers
Vascular Endothelial Growth Factor A
Molecular Biology
Anti-Idiotypic Antibodies
Biomarkers
regorafenib
Mutation
Survival
Antibodies

Keywords

  • Metastatic colon cancer
  • Molecular profiling
  • Regorafenib
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Molecular profiling in the treatment of colorectal cancer : Focus on regorafenib. / Yan, Yiyi; Grothey, Axel F.

In: OncoTargets and Therapy, Vol. 8, 15.10.2015, p. 2949-2957.

Research output: Contribution to journalArticle

@article{7666cb48b0b64a3c9707c9791ba23873,
title = "Molecular profiling in the treatment of colorectal cancer: Focus on regorafenib",
abstract = "Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.",
keywords = "Metastatic colon cancer, Molecular profiling, Regorafenib, Targeted therapy",
author = "Yiyi Yan and Grothey, {Axel F}",
year = "2015",
month = "10",
day = "15",
doi = "10.2147/OTT.S79145",
language = "English (US)",
volume = "8",
pages = "2949--2957",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Molecular profiling in the treatment of colorectal cancer

T2 - Focus on regorafenib

AU - Yan, Yiyi

AU - Grothey, Axel F

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.

AB - Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.

KW - Metastatic colon cancer

KW - Molecular profiling

KW - Regorafenib

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84944746471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944746471&partnerID=8YFLogxK

U2 - 10.2147/OTT.S79145

DO - 10.2147/OTT.S79145

M3 - Article

AN - SCOPUS:84944746471

VL - 8

SP - 2949

EP - 2957

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -